About
Small Molecules
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (24)
Amit Hasija
Amit Hasija
Milestone Pharmaceuticals
team_member
Andrew Saik
Andrew Saik
Milestone Pharmaceuticals
team_member
Anita Holz
Anita Holz
Milestone Pharmaceuticals
team_member
Cameron Szakacs
Cameron Szakacs, PhD
Milestone Pharmaceuticals
team_member
Current Openings
Current Openings
Milestone Pharmaceuticals
team_member
David B
David B. Bharucha, MD, PHD, FACC
Milestone Pharmaceuticals
team_member
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
9
As Collaborator
2
Total Enrollment
4,456
By Phase
PHASE3: 6PHASE2: 3PHASE1: 1
By Status
COMPLETED: 5TERMINATED: 3NOT_YET_RECRUITING: 1RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06716021Lead Sponsor
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
PHASE3Not yet recruiting
750 participants
Started: Jan 31, 2026 · Completed: Jan 31, 2029
NCT05763953Lead Sponsor
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
PHASE2Recruiting
60 participants
Started: Dec 11, 2023 · Completed: Jun 30, 2027
NCT05511870Collaborator
A Study of Etripamil in Healthy Subjects
PHASE1Completed
12 participants
Started: Mar 7, 2023 · Completed: Mar 26, 2023
NCT05410860Collaborator
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
PHASE3Completed
500 participants
Started: Jun 30, 2022 · Completed: Dec 10, 2024
NCT04952610Lead Sponsor
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
PHASE3Enrolling by invitation
130 participants
Started: Dec 13, 2021 · Completed: Mar 31, 2026
Locations (1)
Headquarters
Montréal, QC, Canada
Map
Loading map...